Fluticasone propionate in the management of lower respiratory tract diseases Review article
Article Sidebar
Main Article Content
Abstract
Fluticasone propionate is one of the basic anti-inflammatory drugs used in the management of asthma, chronic obstructive pulmonary disease and other respiratory diseases. Administered as monotherapy or in combination with other drugs (LABA, LABA/LAMA or SABA), fluticasone is characterized by the lowest bioavailability of all topically applied steroids, is highly lipophilic and is metabolized by 99% during the first-pass. Fluticasone improves lung function, reduces the severity of disease symptoms, bronchial hyperresponsiveness and the frequency and severity of exacerbations, as well as improves the quality of life in patients with obstructive lung diseases, and the latest studies indicate its effectiveness in the treatment of post-infectious hyperresponsiveness.
Downloads
Article Details
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med. 2004; 170: 836-44.
3. Lundbäck B, Ronmark E, Lindberg A et al. Asthma control over 3 years in a real-life study. Resp Med. 2009; 103: 348-55.
4. GOLD 2023 guidelines.
5. Pascoe S, Barnes N, Brusselle G et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019; 7(9): 745-56. http://doi.org/10.1016/S2213-2600(19)30190-0.
6. Wouters EFM, Postma DS, Fokkens B et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005; 60(6): 480-7.
7. Speich B, Thomer A, Aghlmandi S et al. Treatments for subacute cough in primary care: systematic review and meta-analyses of randomised clinical trials. Br J Gen Pract. 2018; 68(675): e694-e702.
8. Ponsioen BP, Hop WCJ, Vermue NA et al. Efficacy of fluticasone on cough: a randomised controlled trial. Eur Respir J. 2005; 25(1): 147-52.